462 results about "Dry eyes" patented technology

This invention provides articles and methods for drug delivery including a hydrogel containing one or more drugs for the treatment of a posterior segment disease and / or dry eye conditions. Exemplary drugs are anti-angiogenesis compounds for the treatment of macular degeneration. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

An eyewear apparatus for treating dry eye conditions featuring a pair of curved eyecups having interior cavities for providing treatment to the eyes when worn. Each interior cavity has a sidewall surface adapted to removably engage with the perimeter edge of a moisture pad which may be mounted therein to provide moisture, aroma, or medicinal treatment to the eye. An ocular cavity formed in the moisture pads provides a separate treatment chamber to each of the two eyes of a user. Heat or cold may also be provided to the ocular chamber through temperature components which mount to the moisture pad or in a gap between the moisture pad and the front of the interior cavity.

Described here are devices, systems, and methods for treating one or more conditions (such as dry eye) or improving ocular health by providing stimulation to nasal or sinus tissue. Generally, the devices may be handheld or implantable. In some variations, the handheld devices may have a stimulator body and a stimulator probe having one or more nasal insertion prongs. When the devices and systems are used to treat dry eye, nasal or sinus tissue may be stimulated to increase tear production, reduce the symptoms of dry eye, and / or improve ocular surface health.

An apparatus and system, and methods for using such apparatus and system, is provided for preserving the eye's natural and artificial tears. The apparatus comprises two soft, pliable eyecups, which each include and curved lens and contoured frame, connected by a soft, pliable bridge. The lenses are maintained within a pliable, and contoured frame that is designed and constructed to encircle the orbital bone of the eye sockets, creating a custom fit and effective seal over each eye. Attached to each frame is a gasket that further seals the apparatus over the eyes and provides additional comfort to the wearer. A contoured strap, which is attached to each frame, maintains the position of the apparatus on the wearer.

An eyewear apparatus for treating dry eye conditions featuring a pair of curved eyecups having interior cavities for providing treatment to the eyes when worn. Each interior cavity has a sidewall surface adapted to removably engage with the perimeter edge of a moisture pad which may be mounted therein to provide moisture, aroma, or medicinal treatment to the eye. An ocular cavity formed in the moisture pads provides a separate treatment chamber to each of the two eyes of a user. Heat or cold may also be provided to the ocular chamber through temperature components which mount to the moisture pad or in a gap between the moisture pad and the front of the interior cavity.

A stimulation system stimulates anatomical targets in a patient for treatment of dry eye. The system may include a controller and a microstimulator. The controller may be implemented externally to or internally within the microstimulator. The components of the controller and microstimulator may be implemented in a single unit or in separate devices. When implemented separately, the controller and microstimulator may communicate wirelessly or via a wired connection. The microstimulator may generate pulses from a controller signal and apply the signal via one or more electrodes to an anatomical target. The microstimulator may not have any intelligence or logic to shape or modify a signal. The microstimulator may be a passive device configured to generate a pulse based on a signal received from the controller. The microstimulator may shape or modify a signal. Waveforms having different frequency, amplitude and period characteristics may stimulate different anatomical targets in a patient.

A jojoba formulation has been developed for administration to the meibomian gland, for treatment of the symptoms of dry eye, and / or for drug delivery to the meibomian gland. The formulation incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear as well as stabilize the tear film. The jojoba wax tear relieves irritation and discomfort as well as sharpens the blurred vision. Jojoba, because of its close chemical and physical properties to meibomian gland secretions, is effective upon topical application to penetrate the lid margin to reach the gland tissues where it may exert a therapeutic effect with or without an adjunctive agent.

A stimulation system stimulates anatomical targets in a patient for treatment of dry eye. The system may include a controller and a microstimulator. The controller may be implemented externally to or internally within the microstimulator. The components of the controller and microstimulator may be implemented in a single unit or in separate devices. When implemented separately, the controller and microstimulator may communicate wirelessly or via a wired connection. The microstimulator may generate pulses from a controller signal and apply the signal via one or more electrodes to an anatomical target. The microstimulator may not have any intelligence or logic to shape or modify a signal. The microstimulator may be a passive device configured to generate a pulse based on a signal received from the controller. The microstimulator may shape or modify a signal. Waveforms having different frequency, amplitude and period characteristics may stimulate different anatomical targets in a patient.

The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and / or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.

Controllers for dry eye treatment apparatus and methods are described herein which generally comprise a patch or strip affixed to the skin of the upper and / or lower eyelids to deliver heat to the one or more meibomian glands contained within the underlying skin. The treatment strip or strips include one or more strips configured to adhere to an underlying region of skin in proximity to one or both eyes of a subject such that the one or more strips allow for the subject to blink naturally without restriction from the one or more patches. A controller is in communication with the one or more strips and is programmable to monitor a temperature of the one or more strips to provide a treatment therapy above a threshold temperature of, e.g., 39° C., and below a maximum temperature of, e.g., 48° C., over a treatment period of 12 minutes.

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

This invention provides articles and methods for drug delivery including a hydrogel containing one or more drugs for the treatment of a posterior segment disease and / or dry eye conditions. Exemplary drugs are anti-angiogenesis compounds for the treatment of macular degeneration. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

The invention relates to a drink, in particular to a chrysanthemum health drink strengthening immunity of organisms and suitable to be drunk by various groups, and a preparation method thereof. The honeysuckle health drink is prepared from the following raw materials in portion by weight: chrysanthemum, Chinese wolfberry, honey, citric acid and water of which the ratio is 10-30:5-15:25-45:0.1-1.0:200-400. The chrysanthemum health drink has scientific formula, simple preparation process, good color, aroma and taste, and rich nutrient and is suitable to be drunk by various groups for a long time; the chrysanthemum is adopted as a main raw material, can make people have clear head and bright eyes, and particularly has good treatment effect on excitable computer group with dry eyes caused by eye strain; and the chrysanthemum health drink also has the effects of improving liver function, clearing heat and releasing toxicity, resisting bacteria and diminishing inflammation, strengthening theimmunity and the like, and makes up for the deficiency that carbonated beverage, water, tea, milk and juice beverage only exist in the market but dietetic beverage is absent.

A manual device for massaging one or both of the upper and lower lids of the eye, the device comprising: a body, composed of flexible resilient biocompatible material, wherein the body provides jaws or lips, wherein the lips are biased into a spaced relationship by the material of the body, and wherein each lip is adapted to engage either the upper or lower eyelid, such that movement of the lips causes movement of at least one eyelid with respect to the other. The devices can conveniently be used to manipulate the meibomian glands of the eye in an optimum orientation, for example for alleviating or treating dry eye.

A dry eye treatment device and method of use are disclosed for applying heat to the exterior surface of the eyelid to treat dry eye caused by meibomian gland dysfunction (MGD). More specifically, a user operable main unit and hand piece are provided that allow the user to heat his / her or another patient's eyelids to a desired temperature, which can effectively and efficiently raise the temperature at the meibomian glands to a temperature sufficient to melt, loosen, or soften more serious occlusions or obstructions in the meibomian glands, and restore natural secretory function to obstructed glands.

The present invention provides compositions for treating and / or preventing signs and symptoms associated with dry eye and / or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.

A method for the mitigation of symptoms of dry eye is disclosed. The method involves at least (a) incorporating one or more non-functionalized polymers having one or more hydrophilic moieties into an ophthalmic device that is a polymerization product of a comonomer mixture comprising: (i) a major amount of a non-silicone-containing hydrophilic monomer; and (ii) an end terminal functionalized surfactant; and (b) inserting the ophthalmic device in the eye of a patient.

The present invention relates to methods to treat dry eye in a mammal by intraocularly administering a composition comprising a peptide.

A method of using infrared thermal imager to diagnose eye diseases including the dry eye syndromeuses an infrared thermal imager to take the surface image of the eyeball of the patient. Temperature variation at a specific position of the cornea of the eyeball is precisely measured in a unit time. An attenuation coefficient K of a temperature dropping curve and a temperature difference ΔT are obtained from the temperature variation. Optimized curves of K and ΔT are provided for the doctor to diagnose the patient's eye disease.

Sodium channel blockers represented by the formula:are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.

Eye drops for the treatment of dry eye is disclosed. The eye drops is a solution-type, emulsion-type or two separate phase-type eye drops containing squalane and is, among others, an oil-in-water-type emulsion further containing a water-soluble macromolecular compound such as polyvinylpyrrolidone. Also disclosed are use of squalane for the production of eye drops for the treatment of dry eye, and a method for the treatment of dry eye.

Wipes and their use in methods of treatment of eye disorders such as dry eye or meibomian gland dysfunction.

Remedies for dry eye and diseases associated with dry eye which contain as the active ingredient peptides represented by the general formula (I):H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-X1-Gln-X2-Ala-Val-X3-X4-Tyr-Leu-X5-X6(SEQ ID NOS: 26-36)   (I)wherein X1, X3 and X4 represent Lys or Arg, respectively; X2 represents Met, Leu or nLeu; X5 represents a chemical bond, Asn, Asn-Ser, Asn-Ser-Ile, Asn-Ser-Ile-Leu(SEQ ID NO: 37) or Asn-Ser-Ile-Leu-Asn-X7(SEQ ID NOS: 38-43) (wherein X7 represents a chemical bond, Gly, etc.); and X6 represents —OH or —NH2, or pharmaceutically acceptable salts thereof:.

The present invention relates to a compound of the Formula (I)):or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.